& Paragon Options
Good day, 360!
Here are some of our top movers today. And can’t get enough Lottos? Check out Christian Tharp’s take on them → next trade is TODAY! Be the best prepared trader on the Street!
FOCUS LIST🔎
BPTH – Up over 70% in the pre-market after announcing pre-clinical testing of BP1001-A as potential treatment for obesity in Type 2 diabetes patients enhances insulin sensitivity
VRAR – Up over 25% in pre after announcing it had entered into an agreement with the U.S. Navy for an immersive, AI-driven simulator system
MESO – Up over 40% in pre after announcing its cell therapy treatment for Graft versus Host Disease gets FDA approval
*together with Paragon Options
Every week, Christian Tharp finds 1-3 opportunities that if he opens them on Thursday, they’ll move FAST overnight into Friday. Then, his goal is to close for a massive triple digit gain. He has a brand-new, free presentation showing you how he aims to do this. It’s a ton of fun and can be profitable when he gets it right. He’s only in the trades for less than 24 hours. Find these overnight trades starting TODAY in his free presentation on the next page.
Access Christian’s free presentation on these overnight trades right here.
NEXT TRADE IS TODAY — THURSDAY – SUPER DEAL!
HOTLIST🔥
BPTH – Up over 70% in the pre-market after announcing pre-clinical testing of BP1001-A as potential treatment for obesity in Type 2 diabetes patients enhances insulin sensitivity
Bio-Path Holdings Inc. (BPTH) operates as a clinical and preclinical stage oncology company focused on RNAi nanoparticle drug development in the United States.
In the pre-market this morning, the company announced that results from preclinical studies of BP1001-A for obesity demonstrated enhanced insulin sensitivity, confirming BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients.
P1001-A downregulates growth factor receptor-bound protein 2 (Grb2) expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients.
Shares of BPTH traded up over 70% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $1.61. Beyond that, targets to the upside are $1.87, $2, $2.40 and $2.60.
Below $1.61, targets to the downside are $1.40, $1.30, $1.20, $1.20, $1, $0.90, $0.80 and then a gap fill at $0.6690.
VRAR – Up over 25% in pre after announcing it had entered into an agreement with the U.S. Navy for an immersive, AI-driven simulator system
The Glimpse Group Inc. (VRAR) is an immersive technology company that provides enterprise focused virtual reality (VR), augmented reality (AR), and spatial computing software and services in the United States.
In the pre-market this morning, the company announced that its subsidiary company Brightline Interactive, LLC has entered into an initial six figure dollar contract with the U.S. Navy for an Immersive Simulator, to be delivered in the first half of 2025.
Lyron Bentovim, President and CEO of Glimpse, commented: “In partnership with the US Navy, we believe that the Immersive Simulator represents a key milestone in the world of advanced simulation technology, building on the momentum around Brightline’s vision for the SpatialCore platform.”
Shares of VRAR traded up over 25% in the pre-market in reaction to the news.
The $3.75 area acted as resistance in the after-hours and then became a support level in the pre-market. Above it, targets to the upside are $4.50 and then the pre-market high at $4.95. Beyond that, $5.30 and $7.50 come into play.
Below $3.75, targets to the downside are $3.20, $3 and $2.40 come into place.
MESO – Up over 40% in pre after announcing its cell therapy treatment for Graft versus Host Disease gets FDA approval
Mesoblast Limited (MESO) engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
In the after-hours yesterday, the company announced that the FDA approved Mesoblast Limited’s Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S.
Ryoncil is the only MSC therapy approved in the U.S. for any indication and the only therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents.
Shares of MESO traded up over 40% in the pre-market in reaction to the news.
The $16.20 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $18, $19.57, $21.57 and then the after-hours high at $22.99. Beyond that $27.40 comes into play.
Below $16.20, targets to the downside are $15.60, $15, $14, $13 and then a gap fill at $12.25.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
This post was originally published on here
